• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Improved survival with bufulfan-cyclophosphamide combination vs total body irradiation

byAndrew Bishara
September 28, 2013
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid leukemia (AML) than total body irradiation (TBI).

2. Improved outcomes and greater ease of administration favor BuCy over Cy/TBI for AML patients in first complete remission (CR) undergoing hematopoietic cell transplantation (HCT).

Evidence Rating Level: 2 (Good)

Study Rundown: The most common myeloablative conditioning regimens for allotransplant in AML patients include cyclophosphamide combined with TBI (Cy/TBI) or busulfan (BuCy). However, there are few comparisons of the outcomes of patients receiving these treatments, particularly in light of recent improvements in busulfan administration. Therefore, the goal of this study was to examine the long-term outcomes between these different treatment approaches. The authors found that IV Bu had significantly better outcomes in terms of leukemia free and overall survival. Given the reduced technical requirements of Bu administration compared to TBI, this supports further investigation into the uses of Bu in lieu of the traditional Cy/TBI therapy for this particular patient population. These results benefit from the large number of patients enrolled and the involvement of multiple institutions. However, it should be noted that this was a retrospective study, and patients were not randomly assigned to specific conditioning regimes. Though multivariate analysis corrected for demographic differences between the two treatment groups, several patient characteristics did vary such as age and year of transplantation. There was also variation in the dose of TBI, Bu and Cy. Therefore, future prospective studies into these treatment options may be necessary.

Click to read the study in Blood

Relevant Reading: One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation

RELATED REPORTS

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

In-Depth [retrospective cohort study]: The authors of this study conducted a large, retrospective review of patients from over 500 transplant centers who had undergone first allogeneic HCT with HLA-identical siblings or unrelated donors between 2000 and 2006 for AML in first remission. They examined a total of 1230 patients who had undergone Cy/TBI or BuCy without additional agents, with a median follow-up of surviving patients of 5 years. The primary outcome measured was survival. Other information collected included relapse as defined by hematologic criteria, time to neutrophil and platelet recovery and graft-versus-host disease. The estimated leukemia-free survival and overall survival at 5 years was 41% (95% CI: 37-46%) and 43% (95% CI: 39-47%) for the TBI group, 54% (95% CI: 49-60%)and 61% (95% CI: 56-66%) for oral Bu and 57% (95%CI: 50-64%) and 58% (95% CI: 51-65%) for IV Bu (P < 0.001 for each).

By Monica Parks and Andrew Bishara

More from this author: Adjuvant radiotherapy reduces recurrence of ductal carcinoma; no effect on long-term prognosis, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

 © 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: acute myeloid leukemiaAMLbusulfancyclophosphamideleukemiatotal body irradiation
Previous Post

Secondary mastoid obliteration improves quality of life for patients with chronic otitis media

Next Post

The CRASH-2 trial: Tranexamic acid in trauma patients [Classics Series]

RelatedReports

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy
Chronic Disease

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

May 13, 2022
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma
StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021
#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia
StudyGraphics

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

November 27, 2021
Next Post

The CRASH-2 trial: Tranexamic acid in trauma patients [Classics Series]

Pediatric post-operative intussusception more common in open surgery

Enriching fat grafts with stem cells improves outcomes

Less than one-fifth of patients with hypertension worldwide well controlled

Hypertensive disorders of pregnancy associated with future renal disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.